Figure 2

Average pain reduction effects of Neuragen PN ^® and the placebo, represented by the Visual Analog Scale (VAS), are graphed with a time (pre/post) axis. The VAS ranged from 0-10. The vertical whiskers on each data point represent the standard error about that point. Pre/post pain level was measured 30 minutes before/after treatment applications. There was no significant difference in pain levels before the treatment applications. There was an overall pain reduction for both treatments from pre to post application. Further, Neuragen PN^® had significantly greater pain reduction effects than the placebo (p < .05)